Meridian Bioscience Announces Retirement of Chairman David Phillips
Ohio Pen/10146171

CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022.  The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight.

Mr. Phillips joined the Meridian Board of Directors in 2000 and has served as chairman since September 2018.  During his tenure, Mr. Phillips shepherded the Company through the implementation of Sarbanes-Oxley and numerous acquisitions that form today's Meridian.  The Company has more than twice as many employees and finished fiscal 2021 with net revenues and diluted earnings per share more than five times that of fiscal year 2000.

More on Ohio Pen

• Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
• At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
• Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association
• Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
• Keeping Skills Alive: Cincinnati Family Electricians Pass the Torch to the Next Generation

David Phillips, Chairman of the Board of Directors stated, "It has been an honor to be part of Meridian for the last 21 years.  I have witnessed the transformation and globalization of this business and I am proud of the impact the Company continues to make in healthcare.  Jack has built the strongest management team since I have been part of the organization, and coupled with the expertise of the other directors, I am excited about what the future holds for the Company."

Jack Kenny, CEO said, "Dave has dedicated many years to Meridian as an advisor, leader, and friend.  His contributions over the years are greatly appreciated and his presence around the office and in the board room will be greatly missed."

About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

More on Ohio Pen

• My Hero Academia, One Piece, Dragon Ball Among Anime Voices at FAN EXPO Cleveland, March 13-15
• BarkParkFinder.com Surpasses 50,000 Dog Park Listings Nationwide
• Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
• Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
• Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth

Meridian's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone:  +1 513.271.3700
Email: [email protected]

SOURCE Meridian Bioscience, Inc.

---

Show All News | Report Violation